Prévisions du marché du traitement de l’hématurie en Amérique du Nord jusqu’en 2028 – Impact du COVID-19 et analyse régionale par traitement (médicaments, thérapies et autres), indication (infections des voies urinaires, calculs rénaux, urétrite, cancer du sang, calculs vésicaux, cancer de la prostate, cystite, traumatisme , exercice vigoureux, maladie polykystique des reins, endométriose et menstruations), type (hématurie macroscopique, hématurie microscopique, hématurie idiopathique et hématurie Jogger\'™), utilisateur final (hôpitaux, cliniques et centres chirurgicaux ambulatoires et autres)
Introduction au marché
L\'hématurie est une condition médicale dans laquelle la présence de sang est détectée dans l\'urine. . Généralement, l\'urine ne contient pas de globules rouges, ce qui peut entraîner de graves problèmes pouvant également provoquer des calculs rénaux, des infections des voies urinaires et d\'autres maladies héréditaires.
De plus, l\'hématurie est à forte prévalence. les indications associées devraient soutenir la croissance du marché au cours de la période de prévision. Cependant, des cas non diagnostiqués d\'indications associées limitent la croissance du marché nord-américain du traitement de l\'hématurie.
La pandémie a offert des opportunités de croissance vitales aux acteurs opérant sur le marché des maladies rénales. Ces possibilités étaient dues au nombre croissant de patients touchés par le coronavirus. Par exemple, selon le rapport de l’American Society of Nephrology, en réponse au COVID-19, la moitié des patients positifs au coronavirus admis en unité de soins intensifs (USI) souffrent d’insuffisance rénale qui nécessite une forme de dialyse. Le rapport indiquait qu\'environ 10 à 50 % des patients en soins intensifs présentaient une insuffisance rénale, près de 17 % des patients avaient besoin d\'une dialyse urgente et 46 % avaient présenté certaines formes d\'insuffisance rénale aiguë (IRA). Dans la région nord-américaine, les États-Unis ont enregistré le plus grand nombre de patients touchés par le coronavirus. Ainsi, un nombre croissant de patients courent un risque plus élevé d’être affectés par une lésion rénale aiguë (IRA), notamment une lésion tubulaire accompagnée d’un choc septique, d’une micro-inflammation, d’une augmentation de la coagulation sanguine et d’une probable infection directe du rein. Par conséquent, on s’attend à ce que la demande de produits de gestion des maladies rénales augmente, ce qui entraînera une croissance du marché dans un avenir proche.
Aperçu et dynamique du marché
Le marché nord-américain du traitement de l\'hématurie devrait atteindre 419,7 millions de dollars US d\'ici 2028, contre 351,6 millions de dollars US en 2021 ; il devrait croître à un TCAC de 2,6 % de 2021 à 2028. Les développements technologiques dans les dispositifs médicaux et les procédures de diagnostic ont conduit à diverses options pour gérer les indications associées à l\'hématurie, telles que les calculs rénaux, les calculs vésicaux et les infections des voies urinaires. L’utilisation de technologies de traitement avancées devrait améliorer les soins aux patients. Par exemple, la mise en œuvre de la robotique dans les cabinets chirurgicaux destinés au traitement de la lithiase urinaire a gagné en popularité ces dernières années. Actuellement, le système chirurgical Vinci, d\'Intuitive Surgical Inc., est largement utilisé dans la réalisation d\'interventions chirurgicales pour traiter la lithiase urinaire. De même, le recours aux interventions enourologiques pour les calculs rénaux a considérablement augmenté dans divers pays. On s\'attend également à ce que les progrès dans les indications associées soutiennent le marché nord-américain du traitement de l\'hématurie au cours de la période de prévision.
Segments clés du marché
En termes de type, le segment de l\'hématurie macroscopique représentait la plus grande part du marché nord-américain du traitement de l\'hématurie en 2020. En termes de traitement, les médicaments Le segment représentait la plus grande part du marché du traitement de l’hématurie en Amérique du Nord en 2020. En termes d’indication, le segment des infections des voies urinaires représentait la plus grande part du marché du traitement de l’hématurie en Amérique du Nord en 2020. En termes d’utilisateur final, le segment des hôpitaux représentait la plus grande part du marché nord-américain du traitement de l\'hématurie en 2020.
Principales sources et sociétés répertoriées
Quelques sources primaires et secondaires majeures mentionnées pour la préparation de ce rapport sur le marché du traitement de l\'hématurie en Amérique du Nord sont les sites Web des entreprises, les rapports annuels, les rapports financiers, les documents gouvernementaux nationaux et les bases de données statistiques. , entre autres. Les principales sociétés répertoriées dans le rapport sont AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd et Boehringer Ingelheim International GmbH.
Rapport Raisons d\'acheter
- Comprendre le paysage du marché du traitement de l\'hématurie en Amérique du Nord et identifier les segments de marché qui sont susceptibles de garantir un rendement élevé
- Pour comprendre le paysage du marché en constante évolution et garder une longueur d\'avance face à la concurrence
- Pour planifier efficacement les fusions, les acquisitions et les accords de partenariat sur le marché nord-américain du traitement de l\'hématurie en identifiant les segments avec les ventes probables les plus prometteuses
- Pour prendre des décisions commerciales éclairées à partir d\'une analyse perspicace et complète des les performances du marché de divers segments
- Pour obtenir les prévisions de revenus du marché du traitement de l\'hématurie en Amérique du Nord en fonction de divers segments pour la période 2021-2028
SEGMENTATION DU MARCHÉ DU TRAITEMENT DE L\'HÉMATURIE EN AMÉRIQUE DU NORD
Par Traitement
- Drogues
- Thérapies
- Autres
Par indication
- Infections des voies urinaires
- Calculs rénaux
- Urétrite
- Cancer du sang
- Calculs vésicaux
- Cancer de la prostate
- Cystite
- Traumatisme
- Vigoureux Exercice
- Maladie polykystique des reins
- Endométriose
- Menstruations
Par Type
- Hématurie macroscopique
- Hématurie microscopique
- Hématurie idiopathique
- Hématurie de Jogger
Par utilisateur final
- Hôpitaux
- Cliniques
- Centres chirurgicaux ambulatoires (ASC)
- Autres
Par pays
- Amérique du Nord
- États-Unis
- Canada
- Mexique
Entreprises mentionnées
- AstraZeneca
- Société Bristol-Myers Squibb
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- < span>Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Hematuria Treatment Market – By Treatment
1.3.2 North America Hematuria Treatment Market – By Indication
1.3.3 North America Hematuria Treatment Market – By Type
1.3.4 North America Hematuria Treatment Market – By End User
1.3.5 North America Hematuria Treatment Market – By Country
2. North America Hematuria Treatment Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Hematuria Treatment Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.3 Experts Opinion
5. Hematuria Treatment Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Hematuria-Associated Indications
5.1.2 Increasing Awareness About Treatment Options and Improving Healthcare Expenditure
5.2 Market Restraints
5.2.1 Undiagnosed Cases of Associated Indications
5.3 Market Opportunities
5.3.1 Increasing Opportunities for Related Treatments
5.4 Future Trends
5.4.1 Rise in Preference for Advanced Therapies
5.5 Impact Analysis
6. Hematuria Treatment Market – North America Analysis
6.1 North America Hematuria Treatment Market Revenue Forecast and Analysis
7. Hematuria Treatment Market Revenue and Forecast To 2028 – By Treatment
7.1 Overview
7.2 North America Hematuria Treatment Market Share by Treatment 2020 & 2028 (%)
7.3 Drugs
7.3.1 Overview
7.3.2 Drugs: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Therapies
7.4.1 Overview
7.4.2 Therapies: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Others
7.5.1 Overview
7.5.2 Others: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8. Hematuria Treatment Market Revenue and Forecast To 2028 – By Indication
8.1 Overview
8.2 North America Hematuria Treatment Market Share by Indication 2020 & 2028 (%)
8.3 Kidney Stones
8.3.1 Overview
8.3.2 Kidney Stones: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Urinary Tract Infections (UTI)
8.4.1 Overview
8.4.2 Urinary Tract Infections: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Urethritis
8.5.1 Overview
8.5.2 Urethritis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Blood Cancer
8.6.1 Overview
8.6.2 Blood Cancer: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.7 Bladder Stones
8.7.1 Overview
8.7.2 Bladder Stones: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.8 Prostate Cancer
8.8.1 Overview
8.8.2 Prostate Cancer: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.9 Cystitis
8.9.1 Overview
8.9.2 Cystitis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.10 Trauma
8.10.1 Overview
8.10.2 Trauma: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.11 Vigorous Exercise
8.11.1 Overview
8.11.2 Vigorous Exercise: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.12 Polycystic Kidney Disease
8.12.1 Overview
8.12.2 Polycystic Kidney Disease: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.13 Endometriosis
8.13.1 Overview
8.13.2 Endometriosis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.14 Menstruation
8.14.1 Overview
8.14.2 Menstruation: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
9. Hematuria Treatment Market Revenue and Forecast To 2028 – By Type
9.1 Overview
9.2 North America Hematuria Treatment Market, By Type 2020 & 2028 (%)
9.3 Macroscopic Hematuria
9.3.1 Overview
9.3.2 Macroscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.4 Microscopic Hematuria
9.4.1 Overview
9.4.2 Microscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.5 Idiopathic Hematuria
9.5.1 Overview
9.5.2 Idiopathic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.6 Jogger’s Hematuria
9.6.1 Overview
9.6.2 Jogger’s Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
10. Hematuria Treatment Market Revenue and Forecast To 2028 – By End User
10.1 Overview
10.2 North America Hematuria Treatment Market Share by End User 2020 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Clinics
10.4.1 Overview
10.4.2 Clinics: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.5 Ambulatory Surgical Centers (ASC’s)
10.5.1 Overview
10.5.2 Ambulatory Surgical Centers: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.6 Others
10.6.1 Overview
10.6.2 Others: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
11. North America Hematuria Treatment Market – Geographic Analysis
11.1 North America: Hematuria Treatment Market
11.1.1 Overview
11.1.2 North America: Hematuria Treatment Market, by Country, 2021 & 2028 (%)
11.1.2.1 US: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.1.1 US: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.1.2 US: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
11.1.2.1.3 US: Hematuria Treatment Market, by Indication – Revenue and Forecast to 2028 (USD Million)
11.1.2.1.4 US: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (USD Million)
11.1.2.1.5 US: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (USD Million)
11.1.2.2 Canada: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.2.1 Canada: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.2.2 Canada: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
11.1.2.2.3 Canada: Hematuria Treatment Market, by Indication – Revenue and Forecast to 2028 (USD Million)
11.1.2.2.4 Canada: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (USD Million)
11.1.2.2.5 Canada: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (USD Million)
11.1.2.3 Mexico: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.3.1 Mexico: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.3.2 Mexico: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
11.1.2.3.3 Mexico: Hematuria Treatment Market, by Indication – Revenue and Forecast to 2028 (USD Million)
11.1.2.3.4 Mexico: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (USD Million)
11.1.2.3.5 Mexico: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (USD Million)
12. Impact Of COVID-19 Pandemic on Hematuria Treatment Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
13. Hematuria Treatment Market–Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 AstraZeneca
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Bristol-Myers Squibb Company
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 F. HOFFMANN-LA ROCHE LTD.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 GlaxoSmithKline Plc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Janssen Pharmaceuticals
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck & Co., Inc.
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Pfizer Inc.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Sun Pharmaceutical Industries Ltd
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Boehringer Ingelheim International GmbH
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. US: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 2. US: Hematuria Treatment Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 3. US: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 4. US: Hematuria Treatment Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 5. Canada: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 6. Canada: Hematuria Treatment Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 7. Canada: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Canada: Hematuria Treatment Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)
Table 9. Mexico: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 10. Mexico: Hematuria Treatment Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 11. Mexico: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 12. Mexico: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 13. Organic Developments Done by Companies
Table 14. Inorganic Developments Done by Companies
Table 15. Glossary of Terms, Hematuria Treatment Market
LIST OF FIGURES
Figure 1. Hematuria Treatment Market Segmentation
Figure 2. North America Hematuria Treatment Market Overview
Figure 3. Macroscopic Hematuria Segment Held the Largest Share of the Type Segment in Hematuria Treatment Market
Figure 4. US to Show Significant Growth During Forecast Period
Figure 5. North America Hematuria Treatment Market, Industry Landscape
Figure 6. North America PEST Analysis
Figure 7. Hematuria Treatment Market Impact Analysis of Drivers and Restraints
Figure 8. North America Hematuria Treatment Market – Revenue Forecast and Analysis – 2020- 2028
Figure 9. North America Hematuria Treatment Market Share by Treatment 2020 & 2028 (%)
Figure 10. Drugs: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 11. Therapies: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 12. Others: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 13. North America Hematuria Treatment Market Share by Indication 2020 & 2028 (%)
Figure 14. Kidney Stones: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 15. Urinary Tract Infections: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 16. Urethritis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 17. Blood Cancer: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 18. Bladder Stones: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 19. Prostate Cancer: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 20. Cystitis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 21. Trauma: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 22. Vigorous Exercise: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 23. Polycystic Kidney Disease: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 24. Endometriosis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 25. Menstruation: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 26. North America Hematuria Treatment Market, by Type 2020 & 2028 (%)
Figure 27. Macroscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 28. Microscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 29. Idiopathic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 30. Jogger’s Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 31. North America Hematuria Treatment Market Share by End User 2020 & 2028 (%)
Figure 32. Hospitals: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 33. Clinics: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 34. Ambulatory Surgical Centers: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 35. Others: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 36. North America: Hematuria Treatment Market, by Key Country – Revenue (2021) (USD Million)
Figure 37. North America: Hematuria Treatment Market, by Country, 2021 & 2028 (%)
Figure 38. US: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. Canada: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
Figure 40. Mexico: Hematuria Treatment Market – Revenue and Forecast to 2028 (USD Million)
Figure 41. Impact Of COVID-19 Pandemic in North America Country Markets
Figure 42. Growth Strategies Done by the Companies in the Market, (%)
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America hematuria treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America hematuria treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.